A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients
Monitoring the therapeutic response of colorectal cancer (CRC) patients is crucial to determine treatment strategies; therefore, we constructed a liquid biopsy-based approach for tracking tumor dynamics in non-metastatic (nmCRC) and metastatic (mCRC) patients (<i>n</i> = 55). Serial bloo...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/7/3774 |
| _version_ | 1797439039929843712 |
|---|---|
| author | Barbara Kinga Barták Tamás Fodor Alexandra Kalmár Zsófia Brigitta Nagy Sára Zsigrai Krisztina Andrea Szigeti Gábor Valcz Péter Igaz Magdolna Dank István Takács Béla Molnár |
| author_facet | Barbara Kinga Barták Tamás Fodor Alexandra Kalmár Zsófia Brigitta Nagy Sára Zsigrai Krisztina Andrea Szigeti Gábor Valcz Péter Igaz Magdolna Dank István Takács Béla Molnár |
| author_sort | Barbara Kinga Barták |
| collection | DOAJ |
| description | Monitoring the therapeutic response of colorectal cancer (CRC) patients is crucial to determine treatment strategies; therefore, we constructed a liquid biopsy-based approach for tracking tumor dynamics in non-metastatic (nmCRC) and metastatic (mCRC) patients (<i>n</i> = 55). Serial blood collections were performed during chemotherapy for measuring the amount and the global methylation pattern of cell-free DNA (cfDNA), the promoter methylation of <i>SFRP2</i> and <i>SDC2</i> genes, and the plasma homocysteine level. The average cfDNA amount was higher (<i>p</i> < 0.05) in nmCRC patients with recurrent cancer (30.4 ± 17.6 ng) and mCRC patients with progressive disease (PD) (44.3 ± 34.5 ng) compared to individuals with remission (13.2 ± 10.0 ng) or stable disease (12.5 ± 3.4 ng). More than 10% elevation of cfDNA from first to last sample collection was detected in all recurrent cases and 92% of PD patients, while a decrease was observed in most patients with remission. Global methylation level changes indicated a decline (75.5 ± 3.4% vs. 68.2 ± 8.4%), while the promoter methylation of <i>SFRP2</i> and <i>SDC2</i> and homocysteine level (10.9 ± 3.4 µmol/L vs. 13.7 ± 4.3 µmol/L) presented an increase in PD patients. In contrast, we found exact opposite changes in remission cases. Our study offers a more precise blood-based approach to monitor the treatment response to different chemotherapies than the currently used markers. |
| first_indexed | 2024-03-09T11:47:04Z |
| format | Article |
| id | doaj.art-fe0d3a97b7e044d4a52a72d837f5d4cb |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T11:47:04Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-fe0d3a97b7e044d4a52a72d837f5d4cb2023-11-30T23:21:55ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-03-01237377410.3390/ijms23073774A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer PatientsBarbara Kinga Barták0Tamás Fodor1Alexandra Kalmár2Zsófia Brigitta Nagy3Sára Zsigrai4Krisztina Andrea Szigeti5Gábor Valcz6Péter Igaz7Magdolna Dank8István Takács9Béla Molnár10Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryDepartment of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, HungaryMonitoring the therapeutic response of colorectal cancer (CRC) patients is crucial to determine treatment strategies; therefore, we constructed a liquid biopsy-based approach for tracking tumor dynamics in non-metastatic (nmCRC) and metastatic (mCRC) patients (<i>n</i> = 55). Serial blood collections were performed during chemotherapy for measuring the amount and the global methylation pattern of cell-free DNA (cfDNA), the promoter methylation of <i>SFRP2</i> and <i>SDC2</i> genes, and the plasma homocysteine level. The average cfDNA amount was higher (<i>p</i> < 0.05) in nmCRC patients with recurrent cancer (30.4 ± 17.6 ng) and mCRC patients with progressive disease (PD) (44.3 ± 34.5 ng) compared to individuals with remission (13.2 ± 10.0 ng) or stable disease (12.5 ± 3.4 ng). More than 10% elevation of cfDNA from first to last sample collection was detected in all recurrent cases and 92% of PD patients, while a decrease was observed in most patients with remission. Global methylation level changes indicated a decline (75.5 ± 3.4% vs. 68.2 ± 8.4%), while the promoter methylation of <i>SFRP2</i> and <i>SDC2</i> and homocysteine level (10.9 ± 3.4 µmol/L vs. 13.7 ± 4.3 µmol/L) presented an increase in PD patients. In contrast, we found exact opposite changes in remission cases. Our study offers a more precise blood-based approach to monitor the treatment response to different chemotherapies than the currently used markers.https://www.mdpi.com/1422-0067/23/7/3774colorectal cancercell-free DNADNA methylationhomocysteinetherapeutic response |
| spellingShingle | Barbara Kinga Barták Tamás Fodor Alexandra Kalmár Zsófia Brigitta Nagy Sára Zsigrai Krisztina Andrea Szigeti Gábor Valcz Péter Igaz Magdolna Dank István Takács Béla Molnár A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients International Journal of Molecular Sciences colorectal cancer cell-free DNA DNA methylation homocysteine therapeutic response |
| title | A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients |
| title_full | A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients |
| title_fullStr | A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients |
| title_full_unstemmed | A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients |
| title_short | A Liquid Biopsy-Based Approach for Monitoring Treatment Response in Post-Operative Colorectal Cancer Patients |
| title_sort | liquid biopsy based approach for monitoring treatment response in post operative colorectal cancer patients |
| topic | colorectal cancer cell-free DNA DNA methylation homocysteine therapeutic response |
| url | https://www.mdpi.com/1422-0067/23/7/3774 |
| work_keys_str_mv | AT barbarakingabartak aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT tamasfodor aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT alexandrakalmar aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT zsofiabrigittanagy aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT sarazsigrai aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT krisztinaandreaszigeti aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT gaborvalcz aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT peterigaz aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT magdolnadank aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT istvantakacs aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT belamolnar aliquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT barbarakingabartak liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT tamasfodor liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT alexandrakalmar liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT zsofiabrigittanagy liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT sarazsigrai liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT krisztinaandreaszigeti liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT gaborvalcz liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT peterigaz liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT magdolnadank liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT istvantakacs liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients AT belamolnar liquidbiopsybasedapproachformonitoringtreatmentresponseinpostoperativecolorectalcancerpatients |